Table 1 Characteristics of the whole population studied and of each subgroup treated by methotrexate/etanercept or methotrexate/adalimumab according to the responder/non-responder status in the ESPOIR cohort
Whole population | Patients under MTX/etanercept | Patients under MTX/adalimumab | ||||
|---|---|---|---|---|---|---|
Responders (n=24) | Non responders (n=8) | Responders (n=27) | Non responders (n=5) | |||
Age (years) | 49 ± 2 | 49 ± 3 | 53 ± 5 | 48 ± 2 | 52 ± 6 | |
Female/male ratio | 51/13 | 18/6 | 8/0 | 22/5 | 3/2 | |
Body mass index (kg/m2) | 24.4 ± 0.6 | 24.6 ± 0.7 | 26.9 ± 2.4 | 24.3 ± 1 | 20.5 ± 0.7 | |
Tobacco user (%) | 20% | 25% | 13% | 22% | 0% | |
Disease duration (months) | 32 ± 3 | 35 ± 4 | 46 ± 8 | 26 ± 4 | 21 ± 7 | |
ACR/EULAR criteria fullfillment (%) | 100% | 100% | 100% | 100% | 100% | |
ACR 1987 criteria fulfillment (%) | 88% | 92% | 75% | 85% | 100% | |
Share epitope (at least one) (%) | 64% | 63% | 63% | 52% | 60% | |
DAS 28 ESR | 5.242 ± 0.141 | 5.279 ± 0.248 | 4.780 ± 0.290 | 5.417 ± 0,217 | 4.864 ± 0.573 | |
Tender joint count/28 (n) | 10 ± 1 | 10 ± 1 | 10 ± 3 | 10 ± 1 | 11 ± 4 | |
Swollen joint count/28 (n) | 7 ± 1 | 7 ± 1 | 4 ± 1 | 8 ± 1 | 5 ± 1 | |
ESR 1st hour (mm) | 28 ± 3 | 27 ± 4 | 32 ± 11 | 26 ± 5,0 | 36 ± 8 | |
CRP (mg/L) | 27.1 ± 5.0 | 38.9 ± 10.8 | 30.0 ± 17.7 | 18.6 ± 4.6 | 12.4 ± 7.2 | |
Global activity VAS (by patient) | 59.5 ± 2.7 | 56.3 ± 5.0 | 53.4 ± 5.0 | 64.6 ± 3.9 | 56.2 ± 3.9 | |
Rheumatoid factor IgM | Positivity (%) | 73% | 83% | 63% | 67% | 80% |
Titer (IU/mL) | 202 ± 91 | 360 ± 240 | 72 ± 37 | 115 ± 33 | 123 ± 92 | |
Anti-CCP | Positivity (%) | 64% | 71% | 38% | 63% | 80% |
Titer (AU/mL) | 1013 ± 250 | 1533 ± 589 | 207 ± 115 | 760 ± 228 | 1179 ± 809 | |
HAQ (/3) | 1.04 ± 0.08 | 1.05 ± 0.12 | 1.03 ± 0.21 | 1.02 ± 0.11 | 1.15 ± 0.34 | |
Total Sharp score | 5.7 ± 1.2 | 8.9 ± 2.7 | 2.9 ± 1.7 | 4.6 ± 1.2 | 1.2 ± 1.2 | |
Erosion Sharp score | 2.1 ± 0.7 | 3.5 ± 1.8 | 1.4 ± 1.2 | 1.4 ± 0.6 | 0.7 ± 0.7 | |
Corticoids dose (mg/day) | 4.4 ± 0.6 | 4.2 ± 0.9 | 4.1 ± 1.5 | 4.7 ± 0.9 | 3.4 ± 1.7 | |
MTX dose (mg/week) | 15.9 ± 0.6 | 17.2 ± 0.9 | 16.9 ± 1.0 | 14.3 ± 0.9 | 15.0 ± 1.8 | |